Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Beyonttra (Acoramidis) Approved in Japan as First Near-Complete TTR Stabilizer
Details : Beyonttra (acoramidis) is a next-generation, orally-administered, highly potent, small molecule stabiliser of transthyretin. It is approved for the treatment of Transthyretin Amyloid Cardiomyopathy.
Product Name : Beyonttra
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 27, 2025
Lead Product(s) : Acoramidis Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable